SI-BONE, Inc.
SI-BONE, Inc. (Nasdaq: SIBN) develops and sells medical devices for procedures involving compromised bone, with products addressing sacroiliac joint dysfunction and degeneration, spinal fixation and fusion, and pelvic trauma. Its portfolio includes patented titanium implants and insertion instruments, as well as… From the company’s description.
Over the twelve months to Sep 30, 2026, SI-BONE, Inc. reported revenue of $220.65M, up 14.0% from a year earlier, and a net loss of $13.69M. Its operating margin was −7.6%, and operations generated $6.08M in cash. In fiscal 2025, it reported revenue of $200.93M, up 20.2% from fiscal 2024, and a net loss of $18.90M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What SI-BONE, Inc. does
In the company’s own words
SI-BONE, Inc. (Nasdaq: SIBN) develops and sells medical devices for procedures involving compromised bone, with products addressing sacroiliac joint dysfunction and degeneration, spinal fixation and fusion, and pelvic trauma. Its portfolio includes patented titanium implants and insertion instruments, as well as implantable bone products. Product lines include iFuse, iFuse 3D, iFuse TORQ, iFuse Bedrock Granite, iFuse INTRA and iFuse TORQ TNT. Physicians use these products in minimally invasive sacroiliac joint fusion and stabilization, pelvic fixation during spinal fusion, and treatment of pelvic fractures. Customers include orthopedic and neurological surgeons, interventional spine physicians and orthopedic trauma surgeons; the company sells through its own sales force, third-party agents and international resellers. SI-BONE reports more than 140,000 procedures performed with its products since the first iFuse launch in 2009. At December 31, 2025, its U.S. target customer base included more than 12,000 physicians, and its products had been sold in 38 countries.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- SAN JOSE, CA
- Fiscal year end
- December
- CIK
- 1459839
- SIC
- 3841
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns SI-BONE, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · SI-BONE, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do SI-BONE, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of SI-BONE, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in SI-BONE, Inc.'s last four quarterly filings that the numbers alone won't show?”